Published in today’s (May 24, 2017) Inside Health Policy: “As FDA Ignores Pressure from Appropriators on DQSA, Lawmakers Push FDA to Withdraw Guidance on Compounding, Issue Rule Allowing Practice.”
Congressman Buddy Carter and the International Academy of Compounding Pharmacists (IACP) are both quoted in this piece, questioning why the Food & Drug Administration (FDA) continues to ignore the Drug Quality & Security Act’s (DQSA) Congressional intent on office-use compounding.
From the article – “Reps. Buddy Carter (R-GA) and Chris Stewart (R-UT) and 63 other lawmakers argued in a bipartisan letter to FDA Commissioner Scott Gottlieb Tuesday (May 23) that FDA’s compounding policy goes against congressional intent. At issue is a final guidance released in December, “Prescription Requirement under 503A of the Food, Drug and Cosmetic Act,” that requires that compounders only compound a drug for an individual patient with a prescription, or when a history of prescriptions and an established relationship allows a pharmacist to anticipate receiving a prescription.”
Click here to read the entire article.